HealthyPhase 1NCT02814500
DP-R212 Pharmacokinetic Study Phase I
A Phase 1 study testing DP-R212, Amlodipine and Rosuvastatin in people with Healthy, run by Alvogen Korea.
Trial summary
An open label, randomized, 2-sequence, 2-period, single-dose cross-over study to evaluate the pharmacokinetics characteristics of DP-R212 Read more about this study
- Who is it for?
- Ages 19 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- DP-R212, Amlodipine and Rosuvastatin
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 36 participants
- Where
- No sites listed yet
- Study dates
- Jul 2016to Sep 2016
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 to 45 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- BMI 17.5~30.5
- signed the informed consent form prior to the study participation
Who cannot join
- Clinically significant disease
- Previously donate whole blood within 60 days or component blood within 30 days
- Clinically significant allergic disease
- Taken IP in other trial within 90 days
- An impossible one who participates in clinical trial by investigator's decision including laboratory test result
Trial locations and contacts
No sites are listed yet.
Min-Geol Kim, M.D contact
About this study
Official title: DP-R212 Pharmacokinetic Study Pharmacokinetic Characteristics of DP-R212 in Comparison to Each Component Coadministered in Healthy Volunteers
An open label, randomized, 2-sequence, 2-period, single-dose cross-over study to evaluate the pharmacokinetics characteristics of DP-R212
Read the detailed description
An open label, randomized, 2-sequence, 2-period, single-dose cross-over study to evaluate the pharmacokinetics characteristics of DP-R212, a fixed dose combination compared with coadministration of separate constituents in healthy adult volunteers
- Conditions
- Healthy
- Being tested
- DP-R212, Amlodipine, Rosuvastatin
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DP-R212Drug
Investigational product is prescribed to all of randomized subjects
AmlodipineDrug
Investigational product is prescribed to all of randomized subjects
RosuvastatinDrug
Investigational product is prescribed to all of randomized subjects
| Study group | Role | What they receive |
|---|---|---|
| A group | Experimental | Amlodipine and Rosuvastatin, DP-R212 Receives: Drug: DP-R212; Drug: Amlodipine; Drug: Rosuvastatin |
| B group | Experimental | DP-R212, Amlodipine and Rosuvastatin Receives: Drug: DP-R212; Drug: Amlodipine; Drug: Rosuvastatin |
What is being measured
The primary outcome is the main question the study is designed to answer.
AUClast
Measured: 0,0.5,1, 2, 3, 4, 5, 6, 8, 10, 12, 24,48,72 hr
Cmax
Measured: 0,0.5,1, 2, 3, 4, 5, 6, 8, 10, 12, 24,48,72 hr
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jun 2016 (estimated)
- Study startJul 2016
- Primary completionSep 2016 (estimated)
- Study completionSep 2016 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 36 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Alvogen Korea
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02814500
- Sponsor's protocol ID
- DP-CTR-212-I-02
- Status last verified
- Jun 2016
- First submitted
- 12 Jun 2016
- Last updated
- 27 Jun 2016
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 27 Jun 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- DP-R212 Pharmacokinetic Study Pharmacokinetic Characteristics of DP-R212 in Comparison to Each Component Coadministered in Healthy Volunteers
- ClinicalTrials.gov ID
- NCT02814500
- Acronym / sponsor ID
- DP-CTR-212-I-02
- Conditions
- Healthy
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 36 participants (estimated)
- Lead sponsor
- Alvogen KoreaIndustry (pharma, biotech, devices)
- Study start
- Jul 2016
- Primary completion
- Sep 2016 (estimated)
- Study completion
- Sep 2016 (estimated)
- First posted
- 27 Jun 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
An open label, randomized, 2-sequence, 2-period, single-dose cross-over study to evaluate the pharmacokinetics characteristics of DP-R212
Detailed description
An open label, randomized, 2-sequence, 2-period, single-dose cross-over study to evaluate the pharmacokinetics characteristics of DP-R212, a fixed dose combination compared with coadministration of separate constituents in healthy adult volunteers
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| A group | Experimental | Drug: DP-R212, Drug: Amlodipine, Drug: RosuvastatinAmlodipine and Rosuvastatin, DP-R212 |
| B group | Experimental | Drug: DP-R212, Drug: Amlodipine, Drug: RosuvastatinDP-R212, Amlodipine and Rosuvastatin |
Who may qualify
- Ages
- 19 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- BMI 17.5~30.5
- signed the informed consent form prior to the study participation
Key exclusion criteria (5 listed)
- Clinically significant disease
- Previously donate whole blood within 60 days or component blood within 30 days
- Clinically significant allergic disease
- Taken IP in other trial within 90 days
- An impossible one who participates in clinical trial by investigator's decision including laboratory test result
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DP-R212Investigational product is prescribed to all of randomized subjects | Drug | A group, B group |
| AmlodipineInvestigational product is prescribed to all of randomized subjects | Drug | A group, B group |
| RosuvastatinInvestigational product is prescribed to all of randomized subjects | Drug | A group, B group |
Primary outcome
AUClast
Time frame: 0,0.5,1, 2, 3, 4, 5, 6, 8, 10, 12, 24,48,72 hr
Cmax
Time frame: 0,0.5,1, 2, 3, 4, 5, 6, 8, 10, 12, 24,48,72 hr
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Jun 2016.
- Individual participant dataSharing planned: Undecided
Related trials for Healthy
Not yet recruitingPhase 2
Investigating the Analgesic Potential of (2R,6R)-HNK in Acute Pain in Healthy Volunteers
Healthy Volunteers
RecruitingObservational study
Collection and Analysis of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers
Healthy Volunteers
RecruitingPhase 1
Bioequivalence Study Between YHP2508A and YHR2601 in Healthy Subjects
Healthy Subjects (HS)
Not yet recruitingObservational study
Assessing the Impact of Perceptions of Unpredictability on Objective Measures of Food Consumption and Metabolism
Healthy Volunteer, Obestity
RecruitingObservational study
Relationship Between Great Toe Strength And Symptoms of Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Chemotherapy-induced Peripheral Neuropathy (CIPN), Healthy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Min-Geol Kim, M.D contact
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing DP-R212, Amlodipine and Rosuvastatin in people with Healthy, run by Alvogen Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 27 Jun 2016. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Min-Geol Kim, M.D (mgkim@jbcp.kr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
AUClast (time frame: 0,0.5,1, 2, 3, 4, 5, 6, 8, 10, 12, 24,48,72 hr). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jun 2016.